{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:28:18Z","timestamp":1789576098203,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytotoxic T-lymphocyte\u2013associated protein 4 (CTLA-4) haploinsufficiency is a primary immune-regulatory disorder characterized by T-cell overactivation and multisystem autoimmunity. Malignancies, particularly lymphomas and gastric cancer, have been reported in approximately 12\u201313% of individuals with CTLA-4 haploinsufficiency, but associations with chronic myeloid leukemia (CML) are very rarely described. We report a young adult with genetically and functionally confirmed CTLA-4 haploinsufficiency who developed a triad of BCR-ABL1\u2013positive chronic myeloid leukemia (CML), bullous pemphigoid, and PLA2R-positive membranous glomerulonephritis (MGN), highlighting diagnostic and management lessons across immunology, hematology, dermatology, and nephrology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 21-year-old woman with Hashimoto thyroiditis and iron-deficiency anemia was found to have BCR-ABL1\u2013positive CML. Within months she developed recurrent infections and paraneoplastic blistering disease. Whole-exome sequencing detected a heterozygous CTLA4 c.529_530insT (p.Tyr177LeufsTer2) frameshift; flow cytometry showed reduced CTLA-4 expression, establishing functional haploinsufficiency. Six months later she presented with edema and nephrotic-range proteinuria; serology revealed markedly elevated anti-PLA2R antibodies, and kidney biopsy confirmed immune-complex MGN. Management included a TKI (imatinib\/nilotinib as indicated over the course), low-dose corticosteroids, monthly IVIG for infection\/immune modulation, and rituximab for bullous disease and MGN. This resulted in molecular remission of CML, resolution of skin lesions, and sustained normalization of proteinuria over 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The convergence of CML, bullous pemphigoid, and PLA2R-positive MGN in CTLA-4 haploinsufficiency broadens the clinical phenotype and underscores the importance of considering inborn errors of immunity in young adults with refractory, multisystem autoimmunity and hematologic abnormalities. Early genetic diagnosis can guide targeted immunomodulation and organ preservation, and multidisciplinary care is essential for optimal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-026-01011-7","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T18:35:19Z","timestamp":1769366119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CTLA-4 haploinsufficiency presenting with chronic myeloid leukemia, bullous pemphigoid, and PLA2R-positive membranous nephropathy: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Nouraldeen","family":"Deeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahaldeen","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares Sayed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younis Malik Younis","family":"Amro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Altell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa","family":"khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"issue":"12","key":"1011_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14728222.2022.2170781","volume":"26","author":"M Sadeghi","year":"2022","unstructured":"Sadeghi M, Khodakarami A, Ahmadi A, Fathi M, Navashenaq JG, Mohammadi H, et al. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert Opin Ther Targets. 2022;26(12):1057\u201371. https:\/\/doi.org\/10.1080\/14728222.2022.2170781.","journal-title":"Expert Opin Ther Targets"},{"key":"1011_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2017.07.014","volume":"49","author":"B Lo","year":"2017","unstructured":"Lo B, Abdel-Motal UM. Lessons from CTLA-4 deficiency and checkpoint inhibition. Curr Opin Immunol. 2017;49:14\u20139. https:\/\/doi.org\/10.1016\/j.coi.2017.07.014.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"1011_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12997","volume":"190","author":"N Verma","year":"2017","unstructured":"Verma N, Burns SO, Walker LSK, Sansom DM. Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clin Exp Immunol. 2017;190(1):1\u20137. https:\/\/doi.org\/10.1111\/cei.12997.","journal-title":"Clin Exp Immunol"},{"key":"1011_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100222","volume":"14","author":"J Song","year":"2020","unstructured":"Song J, Liu K, Pinilla-Ibarz J, Zhang H. A case report and case review: chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation. Leuk Res Rep. 2020;14:100222. https:\/\/doi.org\/10.1016\/j.lrr.2020.100222.","journal-title":"Leuk Res Rep"},{"key":"1011_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204564","author":"SP Verma","year":"2015","unstructured":"Verma SP, Subbiah A, Jacob SE, Basu D. Chronic myeloid leukaemia with extreme thrombocytosis. BMJ Case Rep. 2015. https:\/\/doi.org\/10.1136\/bcr-2014-204564.","journal-title":"BMJ Case Rep"},{"issue":"8","key":"1011_CR6","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s40620-023-01751-4","volume":"36","author":"S Ai","year":"2023","unstructured":"Ai S, Yan X, Zhao X, Ye W, Wen Y, Wang J, et al. Malignancy-associated membranous nephropathy: focus on diagnosis and treatment. J Nephrol. 2023;36(8):2355\u201363. https:\/\/doi.org\/10.1007\/s40620-023-01751-4.","journal-title":"J Nephrol"},{"issue":"8","key":"1011_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","volume":"128","author":"B Lo","year":"2016","unstructured":"Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint haploinsufficiency. Blood. 2016;128(8):1037\u201342. https:\/\/doi.org\/10.1182\/blood-2016-04-712612.","journal-title":"Blood"},{"key":"1011_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: from mechanism to autoimmunetherapy. Int Immunopharmacol. 2020;80:106221. https:\/\/doi.org\/10.1016\/j.intimp.2020.106221.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1011_CR9","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","volume":"142","author":"C Schwab","year":"2018","unstructured":"Schwab C, Gabrysch A, Olbrich P, Pati\u00f1o V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4\u2013insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932\u201346. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.055.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1011_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1089\/gtmb.2016.0335","volume":"21","author":"K Wang","year":"2017","unstructured":"Wang K, Zhu Q, Lu Y, Lu H, Zhang F, Wang X, et al. CTLA-4 +49 G\/A polymorphism confers autoimmune disease risk: an updated meta-analysis. Genet Test Mol Biomarkers. 2017;21(4):222\u20137. https:\/\/doi.org\/10.1089\/gtmb.2016.0335.","journal-title":"Genet Test Mol Biomarkers"},{"key":"1011_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02012","author":"D Egg","year":"2018","unstructured":"Egg D, Schwab C, Gabrysch A, Arkwright PD, Cheesman E, Giulino-Roth L, et al. Increased risk for malignancies in 131 affected CTLA4 mutation carriers. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.02012.","journal-title":"Front Immunol"},{"key":"1011_CR12","unstructured":"Linear Graph-123890-Cytotoxic T lymphocyte-associated 4; CTLA4 - OMIM-(OMIM.Org). Available from: https:\/\/omim.org\/graph\/linear\/123890"},{"issue":"6","key":"1011_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441\u201353. https:\/\/doi.org\/10.1038\/nrc2147.","journal-title":"Nat Rev Cancer"},{"key":"1011_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204564","author":"SP Verma","year":"2015","unstructured":"Verma SP, Subbiah A, Jacob SE, Basu D. Chronic myeloid leukaemia with extreme thrombocytosis. BMJ Case Rep. 2015. https:\/\/doi.org\/10.1136\/bcr-2014-204564.","journal-title":"BMJ Case Rep"},{"issue":"3","key":"1011_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","volume":"29","author":"M Hertl","year":"2014","unstructured":"Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 guideline for diagnosis and treatment\u2013guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2014;29(3):405\u201314. https:\/\/doi.org\/10.1111\/jdv.12772.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1011_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.761600","author":"S Purohit","year":"2021","unstructured":"Purohit S, Piani F, Ordo\u00f1ez FA, De Lucas-Collantes C, Bauer C, Cara-Fuentes G. Molecular mechanisms of proteinuria in minimal change disease. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.761600.","journal-title":"Front Med"},{"issue":"11","key":"1011_CR17","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1093\/ndt\/gft381","volume":"28","author":"C Spink","year":"2013","unstructured":"Spink C, Stege G, Tenbrock K, Harendza S. The CTLA-4 +49GG genotype is associated with susceptibility for nephrotic kidney diseases. Nephrol Dial Transplant. 2013;28(11):2800\u20135. https:\/\/doi.org\/10.1093\/ndt\/gft381.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1011_CR18","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00467-014-2874-8","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH. Minimal change disease: A dysregulation of the podocyte CD80\u2013CTLA-4 axis? Pediatr Nephrol. 2014;29(12):2333\u201340. https:\/\/doi.org\/10.1007\/s00467-014-2874-8.","journal-title":"Pediatr Nephrol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-026-01011-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:07:08Z","timestamp":1781629628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-026-01011-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1186\/s13223-026-01011-7","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The patient reported that her illness had significantly impacted her daily life, especially due to the persistent infections and skin lesions. She expressed relief after receiving a definitive diagnosis and reported noticeable improvement in her symptoms after beginning therapy. Despite the complexity of her condition, she felt supported by the medical team and expressed hope for continued improvement with ongoing care.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Perspective"}}],"article-number":"5"}}